C17orf49

Across TCGA pan-cancer cohorts, C17orf49 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C17orf49 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C17orf49 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C17orf49 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where C17orf49 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.453	0.184	.008	18	view →
LSCC	OS	Tertile	III,IV	0.434	0.876	.024	8	view →
LUAD	OS	Quartile	All	0.892	0.570	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C17orf49–PDAC (DFS)

Open the PDAC breakdown →